Literature DB >> 24918025

Hemichorea Associated with CASPR2 Antibody.

Iryna Vynogradova1, Vitali Savitski1, Josef G Heckmann1.   

Abstract

This letter was written in response to: Ramdhani RA, Frucht SJ. Isolated chorea associated with LGI1 antibody. Tremor Other Hyperkinet Mov. 2014; 4. doi: 10.7916/D8MG7MFC.

Entities:  

Keywords:  CASPR2 antibody; Choreatic syndrome; chorea; hemichorea; paraneoplastic syndrome

Year:  2014        PMID: 24918025      PMCID: PMC4039192          DOI: 10.7916/D8VM49C5

Source DB:  PubMed          Journal:  Tremor Other Hyperkinet Mov (N Y)        ISSN: 2160-8288


To the editor: We read with great interest the article "Isolated Chorea Associated with LGI1 Antibody" (LGI1, leucine-rich glioma inactivated 1) by Ramdhani and Frucht.1 The authors presented an important clinical observation about a treatable etiology of chorea in a 53-year-old male, in whom an underlying tumor could not be detected. By presenting a case vignette of hemichorea associated with antibodies against contactin-associated protein 2 (CASPR2), we wish to emphasize the relationship between a movement disorder and an autoantibody. In our patient, lung cancer was detected. A 75-year-old female developed choreiform movement disorder, predominantly affecting the left limbs and the left side of the face. She took no neuroleptic drugs and reported that she had been smoking for about 50 years. Her family history was unremarkable. Cranial magnetic resonance images and serum chemistry, including liver enzymes, complete blood count, thyroid function, and cerebrospinal fluid analysis were negative. Her creatine kinase level was slightly elevated, due to the movement disorder (325 U/L, normal <140). Systemic lupus erythematosus and neuroacanthocytosis were not clinically suspected, and tests for these conditions were not performed. Electroencephalography (EEG) revealed normal background activity without signs of epileptic discharges. As a paraneoplastic process was suspected,2 computed tomography-positron emission tomography (CT-PET) was performed and revealed a right-side malignant lung tumor. Based on the patient's history and radiological presentation, it was perceived as smoking-associated lung cancer. Serum analysis for paraneoplastic autoantibodies detected CASPR2 antibodies by indirect immunofluorescence test (titer IgM 1:10; Euroimmun, Lübeck, Germany). Tests for the remainder of the autoantibodies (anti-Hu, -Ri, -Yo, -CV2, -Ma, -Ta, -PCA2, -ANNA, -NMDA, -AMPA-1, and -AMPA-2) were negative. Symptomatic treatment with tiapride (200 mg daily) was introduced and resulted in acceptable symptom control within the following 2 days. Although oncologic therapy was proposed, it was refused by the patient. Through this case vignette, we wish to complement the observations of Ramdhani and Frucht1 and Tofaris et al.3 for two reasons. First, autoimmune processes (both paraneoplastic and idiopathic) are well-recognized causes of chorea but are relatively rare.4 In most cases, co-existing neurological findings, such as peripheral neuropathy, cognitive decline, epilepsy, or oculomotor disturbances, are present.5 In the Ramdhani and Frucht1 case, and even in our case, isolated chorea and hemichorea, respectively, were the index symptom. Whereas an idiopathic etiology was strongly assumed in the case of Ramdhani and Frucht,1 in our case, an obvious paraneoplastic etiology has to be considered. The pronounced CT-PET-findings and the history of excessive smoking led us to suspect a smoking-associated lung cancer. However, a histological tissue diagnosis was refused by the patient, as was subsequent oncologic therapy. Second, the isolated pattern of CASPR2 autoantibody positivity is interesting. Only one case of autoimmune chorea with a positive CASPR2 antibody has been reported, and it was an idiopathic case. This is according to a study on autoimmune chorea in adults,4 in which the case of Ramdhani and Frucht1 can also be grouped. In the paraneoplastic group of autoimmune chorea, CASPR2 has not yet been reported.4 On the other hand, CASPR2 is more often associated with neuromyotonia and Morvan syndrome and occurs more often in thymoma,6 though these clinical findings were not present in our patient. However, it is informative that LGI1 (the antibody detected in the patients of Ramdhani and Frucht1 and of Toranis et al.3) and CASPR2 are taken together as voltage-gated potassium channel (VGKC) complex autoantibodies and thus share substantial similarity.7,8 To conclude, autoimmune processes must be considered in the differential diagnosis of adult-onset chorea. Besides laboratory and cerebrospinal fluid analysis,9,10a serum panel of autoantibodies, including LGI1 and CASPR2, may contribute to the diagnosis.
  10 in total

1.  Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.

Authors:  George K Tofaris; Sarosh R Irani; Binith J Cheeran; Ian W S Baker; Zameel M Cader; Angela Vincent
Journal:  Neurology       Date:  2012-06-27       Impact factor: 9.910

2.  Chorea resulting from paraneoplastic encephalitis.

Authors:  J G Heckmann; C J Lang; A Druschky; D Claus; O Bartels; B Neundörfer
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

Review 3.  Movement disorders in paraneoplastic and autoimmune disease.

Authors:  Jessica Panzer; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

Review 4.  Caspr2 antibodies in patients with thymomas.

Authors:  Angela Vincent; Sarosh R Irani
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

5.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

6.  Autoimmune chorea in adults.

Authors:  Orna O'Toole; Vanda A Lennon; J Eric Ahlskog; Joseph Y Matsumoto; Sean J Pittock; James Bower; Robert Fealey; Daniel H Lachance; Andrew McKeon
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

7.  Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.

Authors:  Christopher J Klein; Vanda A Lennon; Paula A Aston; Andrew McKeon; Orna O'Toole; Amy Quek; Sean J Pittock
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

8.  Paraneoplastic syndromes and autoimmune encephalitis: Five new things.

Authors:  Myrna R Rosenfeld; Maarten J Titulaer; Josep Dalmau
Journal:  Neurol Clin Pract       Date:  2012-09

9.  Choreoathetosis related to lithium intoxication.

Authors:  B Stemper; N Thürauf; B Neundörfer; J G Heckmann
Journal:  Eur J Neurol       Date:  2003-11       Impact factor: 6.089

10.  Isolated Chorea Associated with LGI1 Antibody.

Authors:  Ritesh A Ramdhani; Steven J Frucht
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-01-08
  10 in total
  4 in total

1.  Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.

Authors:  Sudheeran Kannoth; Vivek Nambiar; Siby Gopinath; Anandkumar Anandakuttan; Annamma Mathai; Parvathy Kanjiramana Rajan
Journal:  Neurol Sci       Date:  2017-12-20       Impact factor: 3.307

2.  Eyelid tremor in a patient with anti-caspr2 antibody-related encephalitis.

Authors:  Shuichi Ueno; Makito Hirano; Hikaru Sakamoto; Susumu Kusunoki; Yusaku Nakamura
Journal:  Case Rep Neurol       Date:  2014-08-27

Review 3.  Antibody-related movement disorders - a comprehensive review of phenotype-autoantibody correlations and a guide to testing.

Authors:  Felix Gövert; Frank Leypoldt; Ralf Junker; Klaus-Peter Wandinger; Günther Deuschl; Kailash P Bhatia; Bettina Balint
Journal:  Neurol Res Pract       Date:  2020-02-20

4.  Clinical Profile and Treatment Response in Patients with CASPR2 Antibody-Associated Neurological Disease.

Authors:  Sumanth Shivaram; Madhu Nagappa; Doniparthi V Seshagiri; Anita Mahadevan; Yashwanth Gangadhar; T N Sathyaprabha; Vijay Kumavat; Rose D Bharath; Sanjib Sinha; Arun B Taly
Journal:  Ann Indian Acad Neurol       Date:  2021-03-31       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.